Year: 2019

Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that it has raised an additional £14 million bringing its total Series A financing to £30 million. The financing includes funding from Seroba, as a new investor. STORM’s existing investors, Cambridge Innovation Capital, M Ventures, Pfizer …

Seroba Invests in Storm Therapeutics Read More »

Quanta SC+

Quanta SC+ confirmed as safe and easy to use

Alcester, Warwickshire, UK, 15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical technology company developing a personal haemodialysis system (SC+) for patient use in the clinic and the home, today announced that results from its human factors testing (HFT) of SC+ have been published in Hemodialysis International, …

Quanta SC+ confirmed as safe and easy to use Read More »

Fusion

Fusion Raises $105m in Series B Financing

April 2nd 2019. Hamilton, Canada and Dublin, Ireland.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the completion of a $105 million Series B financing led by Varian and new investor OrbiMed Advisors. Seroba participated in the round alongside new investors including Perceptive Advisors, Pivotal …

Fusion Raises $105m in Series B Financing Read More »

Jen Moderator Session On Investment Cycles

VCs with €6Bn in Funds to Invest Visit Dublin

The sixth annual MedTech Strategist Innovation Summit Dublin will take place this April in the Shelbourne Hotel. Dozens of Venture Capital firms whose funds together amount to over €6 billion will attend the Summit, which is expected to attract some of the most promising medtech innovations from throughout Europe, the U.S. and Asia. As platinum …

VCs with €6Bn in Funds to Invest Visit Dublin Read More »

Fusion News

First Patient Dosed in Fusion Phase I trial

Boston, Massachusetts & Hamilton, Ontario. February 19, 2019.  Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors. “The entire Fusion team takes tremendous pride in …

First Patient Dosed in Fusion Phase I trial Read More »

Labcyte News Logo

Labcyte Sold to Beckman Coulter

Dublin, Ireland. 30 January 2019. Seroba portfolio company, Labcyte, has been acquired by Beckman Coulter Life Sciences, part of the larger Danaher Corporation which generates approximately $6.5 billion in annual revenue. Labcyte is best known for its Echo® acoustic droplet ejection technology, which uses sound waves to transfer tiny amounts of liquid with unequalled speed and …

Labcyte Sold to Beckman Coulter Read More »

Pq Bypass

PQ Bypass Announces $60M Financing

PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease. Funds Will Support Pivotal Trial of Novel DETOUR System Designed for Patients with Tough to Treat Long Blockages in Leg Arteries. January 08, 2019. Ireland and California, USA. Seroba’s portfolio company, PQ Bypass, Inc., a medical device company dedicated to …

PQ Bypass Announces $60M Financing Read More »

Atlantic Innovo News

Atlantic Therapeutics Raise €28M in Series B Funding

Seroba portfolio company, Atlantic Therapeutics, has raised €28 million following FDA approval for its INNOVO® therapy device to treat incontinence. This funding facilitates the company’s next growth phase, including geographic expansion to US and other markets, new product launches and expanded indications for the INNOVO® therapy platform. Galway, Ireland, 7 January 2019. Atlantic Therapeutics, the …

Atlantic Therapeutics Raise €28M in Series B Funding Read More »

Quanta News

Quanta Appoints New Chief Medical Officer

Alcester, UK, 4 Jan 2019: Seroba portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical device company providing innovative haemodialysis solutions for clinic and home settings, today announced the Company has appointed Dr Paul Komenda as CMO. Quanta has also announced that it will be at the JP Morgan Healthcare Conference in …

Quanta Appoints New Chief Medical Officer Read More »

T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top